Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
SS-31: Evidence Summary
Evidence summary for SS-31 across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to SS-31 overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Heart failure | Tier B | 2 | Phase II trials (elamipretide) showed improved cardiac function in HFrEF patients |
| Mitochondrial dysfunction | Tier C | 3 | Barth syndrome and primary mitochondrial myopathy trials show functional improvement |
| Age-related decline | Tier C | 1 | Improved exercise tolerance in elderly subjects; mechanism via cardiolipin stabilization |